PSMA Targeted Therapy VL

ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor

Details
Oliver Sartor discusses the ProstACT GLOBAL trial design, examining TLX591, a PSMA-targeting antibody bound to lutetium-177 for metastatic castration-resistant prostate cancer treatment. The phase III trial includes a 30-patient safety lead-in followed by a 400-patient randomized study comparing standard of care (ARPI switch or docetaxel) with or without TLX591. Unlike other PSMA-targeted therapie...

Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann

Details
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences i...

Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist

Details
Zachary Klaassen and Luke Nordquist discuss TheranosticTrials.org, a comprehensive global website dedicated to theranostic education and clinical trial information. Dr. Nordquist explains how the platform has expanded from initially covering 150 trials across 12 cancer types to now featuring over 600 trials for 35 different cancers. The website serves as an educational resource for patients, physi...

Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett

Details
Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...

ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu

Details
Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...

Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck

Details
Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...

Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann

Details
Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...

Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant

Details
Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...

Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa

Details
Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...

Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman

Details
Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...